Tomoya Uehara

16PUBLICATIONS
16CO-AUTHORS
Radiation therapyGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 08, 2026
Development of NOTA-based antibody-fragment labeling agent that reduces early renal radioactivity levels.

|Sep 03, 2025
Precision targeting of the melanocortin-1 receptor with radiopharmaceuticals in metastatic melanoma.

Hiroyuki Suzuki, Tomoya Uehara

|Feb 10, 2025
Evaluation of the Gly-Phe-Lys Linker to Reduce the Renal Radioactivity of a [64Cu]Cu-Labeled Multimeric cRGD Peptide.

Zhao-Hui Jin, Mélissa Degardin, Takako Furukawa

|Jan 19, 2025
An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma.

Hiroyuki Suzuki, Saki Yamashita, Shoko Tanaka

|Jun 17, 2024
In vivo stable 211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure.

Hiroyuki Suzuki, Kento Kannaka, Mizuki Hirayama

|Feb 26, 2024
Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics.

Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe

Pageof 3

Frequent Collaborators

10 joint publications

Hiroyuki Suzuki

7 joint publications

Yasushi Arano

4 joint publications

Yuki Mizuno

2 joint publications

Hiroshi Tanaka